| Abstrakt: |
Researchers from Xinqiao Hospital of Army Medical University have conducted a study on acute lymphoblastic leukemia, focusing on the use of donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopoietic stem cell transplantation. The study found that this treatment option resulted in good long-term survival rates, with 2-year overall survival and event-free survival rates of 56.25% and 50.0%, respectively. The research supports donor-derived CAR-T cell therapy as a recommended treatment for relapsed B-ALL patients post-transplantation. [Extracted from the article] |
